The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | Long-term follow-up of tafasitamab and lenalidomide in R/R DLBCL
Wojciech Jurczak, MD, PhD, Jagiellonian University, Krakow, Poland, comments on the prolonged follow-up data of the combination of tafasitamab and lenalidomide in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The results demonstrated deep, long-lasting complete remissions (CR) with no new toxicity signals. In addition, Dr Jurczak explains that tafasitamab treatment does not appear to impact subsequent treatment with CD19 CAR-T therapy. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
